From insulin to incretins: a report from the 67th scientific sessions of the American Diabetes Association.
Rabasseda
X
X
Prous Science Medical Information Department.
D001645:Biguanides / Q000627:therapeutic use; D048909:Diabetes Complications / Q000628:therapy; D003920:Diabetes Mellitus / Q000628:therapy*; D004032:Diet; D019587:Dietary Supplements; D054873:Dipeptidyl-Peptidase IV Inhibitors; D050171:Dyslipidemias / Q000517:prevention & control; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives / Q000627:therapeutic use; D009765:Obesity / Q000517:prevention & control; D045162:Thiazolidinediones / Q000627:therapeutic use
D001645:Biguanides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D052216:Glucagon-Like Peptide 1